IP Library › Granted Patent US 9,795,669
Granted Patent B2
US 9,795,669 · App. 14/969,483 · Granted Oct 24, 2017

Lipidated immune response modifier compound compositions, formulations, and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,669
App. No.
14/969,483
Granted
Oct 24, 2017
Kind
B2
Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

Claims (2)

1. A method of inducing formation of tumor necrosis factor in a human or animal in need thereof, the method comprising administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)-octadecanamide, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is in a liposome formulation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066430/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: WIGHTMAN, PAUL D.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 039481/0031 →